Imdelltra (Amg 757)
Payments companies reported to CMS as associated with Imdelltra (Amg 757). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Imdelltra (Amg 757), per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Imdelltra (Amg 757)
These are the largest totals companies reported as associated with Imdelltra (Amg 757). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Robert Kaner | New York, NY | Pulmonary Disease | $10,976.00 |
| Jeffrey Clarke | Durham, NC | $8,840.00 | |
| Philip Lammers | Bartlett, TN | Hematology & Oncology | $3,211.34 |
| Frederick Schnell | Macon, GA | $3,000.00 | |
| Rafael Santana Davila | Seattle, WA | Hematology & Oncology | $2,716.54 |
| Martin Dietrich | Rockledge, FL | Hematology & Oncology | $717.25 |
| Jacob Sands | Burlington, MA | Hematology & Oncology | $686.00 |
| Eric Nadler | Dallas, TX | Medical Oncology | $649.00 |
| Jared Weiss | Chapel Hill, NC | Hematology & Oncology | $486.75 |
| Amanda Brink | Houston, TX | Family | $425.28 |
Prescribed Imdelltra (Amg 757)?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.